FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Hum Gene Ther / Humoral and cell-mediated immune response, and growth factor...
Human gene therapy2015; 26(3); 161-171; doi: 10.1089/hum.2014.050

Humoral and cell-mediated immune response, and growth factor synthesis after direct intraarticular injection of rAAV2-IGF-I and rAAV5-IGF-I in the equine middle carpal joint.

Abstract: Intraarticular (IA) administration of viral vectors expressing a therapeutic transgene is an attractive treatment modality for osteoarthritis (OA) as the joint can be treated as a contained unit. Humoral and cell-mediated immune responses in vivo can limit vector effectiveness. Transduction of articular tissues has been investigated; however, the immune response to IA vectors remains largely unknown. We hypothesized that IA rAAV2 and rAAV5 overexpressing insulin-like growth factor-I (IGF-I) would result in long-term IGF-I formation but would also induce neutralizing antibodies (NAb) and anti-capsid effector T cells. Twelve healthy horses were assigned to treatment (rAAV2 or rAAV5) or control (saline) groups. Middle carpal joints were injected with 5×10(11) vector genomes/joint. Synovial fluid was analyzed for changes in composition, NAb titers, immunoglobulin isotypes, proinflammatory cytokines, and IGF-I. Serum was analyzed for antibody titers and cytokines. A T cell restimulation assay was used to assess T cell responses. Injection of rAAV2- or rAAV5-IGF-I did not induce greater inflammation compared with saline. Synovial fluid IGF-I was significantly increased in both rAAV2- and rAAV5-IGF-I joints by day 14 and remained elevated until day 56; however, rAAV5 achieved the highest concentrations. A capsid-specific T cell response was not noted although all virus-treated horses had increased NAbs in serum and synovial fluid after treatment. Taken together, our data show that IA injection of rAAV2- or rAAV5-IGF-I does not incite a clinically detectable inflammatory or cell-mediated immune response and that IA gene therapy using minimally immunogenic vectors represents a clinically relevant tool for treating articular disorders including OA.
Get Full Text
Publication Date: 2015-02-24 PubMed ID: 25705927PubMed Central: PMC4367237DOI: 10.1089/hum.2014.050Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • N.I.H.
  • Extramural

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research paper discusses an examination of the immune system’s response and growth factor synthesis following direct intra-articular injection of Recombinant Adeno-Associated Virus 2 and 5 (rAAV2 and rAAV5) with insulin-like growth factor-I (IGF-I) into horses’ middle carpal joint. The findings suggest that this technique does not cause significant inflammation or immune response, making it a potentially viable innovative treatment for articular disorders including osteoarthritis (OA).

Objective and Methodology

  • The researchers hypothesized that a direct joint injection of rAAV2 and rAAV5 carrying the IGF-I gene would stimulate the production of IGF-I, a growth factor beneficial for joint health. They were also investigating whether this process would trigger an immune response that could limit the therapy’s effectiveness.
  • The study utilized twelve healthy horses assigned to either treatment groups or control groups. Treatment consisted of IA injections of either rAAV2-IGF-I or rAAV5-IGF-I, while the control group received saline.
  • Over time, the researchers analyzed synovial fluid for alterations in composition, neutralizing antibodies titers, immunoglobulin isotypes, pro-inflammatory cytokines, and IGF-I levels. They also scrutinized serum for antibody titers and cytokines. A T cell restimulation assay was used to measure T cell responses.

Findings

  • The result showed no significant inflammation after injection of either rAAV2 or rAAV5. It was observed that the IGF-I content in the synovial fluid increased markedly in both rAAV2 and rAAV5 injected joints by day 14 after injection and remained higher until day 56.
  • The rAAV5 treatment group achieved the highest concentrations of IGF-I. All horses treated with the virus indicated an increase in neutralizing antibodies in serum and synovial fluid after the treatment was administered.
  • Interestingly, the experiment did not identify an increase in T cell responses, despite the rise in neutralizing antibodies.

Conclusion

  • Based on the findings, the research concludes that IA gene therapies using minimally immunogenic vectors such as rAAV2 or rAAV5 do not invoke a damaging immune response or clinically significant inflammation.
  • This makes them potentially useful tools in the treatment of articular disorders, including osteoarthritis.

Cite This Article

APA
Ortved K, Wagner B, Calcedo R, Wilson J, Schaefer D, Nixon A. (2015). Humoral and cell-mediated immune response, and growth factor synthesis after direct intraarticular injection of rAAV2-IGF-I and rAAV5-IGF-I in the equine middle carpal joint. Hum Gene Ther, 26(3), 161-171. https://doi.org/10.1089/hum.2014.050

Publication

Human gene therapy
ISSN: 1557-7422
NlmUniqueID: 9008950
Country: United States
Language: English
Volume: 26
Issue: 3
Pages: 161-171

Researcher Affiliations

Ortved, Kyla
  • 1 Department of Clinical Sciences, Cornell University College of Veterinary Medicine , Ithaca, NY 14853.
Wagner, Bettina
    Calcedo, Roberto
      Wilson, James
        Schaefer, Deanna
          Nixon, Alan

            MeSH Terms

            • Animals
            • Antibodies, Neutralizing / immunology
            • Carpal Joints / immunology
            • Dependovirus
            • Genetic Vectors / administration & dosage
            • Genetic Vectors / pharmacology
            • Horses
            • Immunity, Cellular / drug effects
            • Immunity, Humoral / drug effects
            • Immunoglobulin Isotypes / immunology
            • Injections, Intra-Articular
            • Insulin-Like Growth Factor I / pharmacology
            • Intercellular Signaling Peptides and Proteins / biosynthesis
            • Real-Time Polymerase Chain Reaction
            • Spectrophotometry, Ultraviolet
            • Statistics, Nonparametric
            • Synovial Membrane / chemistry

            Grant Funding

            • 5R01-AR055373 / NIAMS NIH HHS
            • P30-DK047757 / NIDDK NIH HHS

            References

            This article includes 40 references
            1. Strauss EJ, Goodrich LR, Chen CT, Hidaka C, Nixon AJ. Biochemical and biomechanical properties of lesion and adjacent articular cartilage after chondral defect repair in an equine model.. Am J Sports Med 2005 Nov;33(11):1647-53.
              pubmed: 16093540doi: 10.1177/0363546505275487google scholar: lookup
            2. Goodrich LR, Brower-Toland BD, Warnick L, Robbins PD, Evans CH, Nixon AJ. Direct adenovirus-mediated IGF-I gene transduction of synovium induces persisting synovial fluid IGF-I ligand elevations.. Gene Ther 2006 Sep;13(17):1253-62.
              pubmed: 16708081doi: 10.1038/sj.gt.3302757google scholar: lookup
            3. Lee HH, O'Malley MJ, Friel NA, Payne KA, Qiao C, Xiao X, Chu CR. Persistence, localization, and external control of transgene expression after single injection of adeno-associated virus into injured joints.. Hum Gene Ther 2013 Apr;24(4):457-66.
              pmc: PMC3631018pubmed: 23496155doi: 10.1089/hum.2012.118google scholar: lookup
            4. Payne KA, Lee HH, Haleem AM, Martins C, Yuan Z, Qiao C, Xiao X, Chu CR. Single intra-articular injection of adeno-associated virus results in stable and controllable in vivo transgene expression in normal rat knees.. Osteoarthritis Cartilage 2011 Aug;19(8):1058-65.
              pmc: PMC3139006pubmed: 21571082doi: 10.1016/j.joca.2011.04.009google scholar: lookup
            5. Fortier LA, Lust G, Mohammed HO, Nixon AJ. Coordinate upregulation of cartilage matrix synthesis in fibrin cultures supplemented with exogenous insulin-like growth factor-I.. J Orthop Res 1999 Jul;17(4):467-74.
              pubmed: 10459751doi: 10.1002/jor.1100170403google scholar: lookup
            6. Fortier LA, Mohammed HO, Lust G, Nixon AJ. Insulin-like growth factor-I enhances cell-based repair of articular cartilage.. J Bone Joint Surg Br 2002 Mar;84(2):276-88.
              pubmed: 11922373doi: 10.1302/0301-620x.84b2.11167google scholar: lookup
            7. Fosang AJ, Tyler JA, Hardingham TE. Effect of interleukin-1 and insulin like growth factor-1 on the release of proteoglycan components and hyaluronan from pig articular cartilage in explant culture.. Matrix 1991 Feb;11(1):17-24.
              pubmed: 2027327doi: 10.1016/s0934-8832(11)80223-4google scholar: lookup
            8. Pelletier JP, Caron JP, Evans C, Robbins PD, Georgescu HI, Jovanovic D, Fernandes JC, Martel-Pelletier J. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy.. Arthritis Rheum 1997 Jun;40(6):1012-9.
              pubmed: 9182910doi: 10.1002/art.1780400604google scholar: lookup
            9. Gouze E, Pawliuk R, Gouze JN, Pilapil C, Fleet C, Palmer GD, Evans CH, Leboulch P, Ghivizzani SC. Lentiviral-mediated gene delivery to synovium: potent intra-articular expression with amplification by inflammation.. Mol Ther 2003 Apr;7(4):460-6.
              pubmed: 12727108doi: 10.1016/s1525-0016(03)00024-8google scholar: lookup
            10. Daya S, Berns KI. Gene therapy using adeno-associated virus vectors.. Clin Microbiol Rev 2008 Oct;21(4):583-93.
              pmc: PMC2570152pubmed: 18854481doi: 10.1128/cmr.00008-08google scholar: lookup
            11. Begum L, Ortved KF, Nixon AJ. AAV-5 provides more efficient transgene expression in chondrocytes grown in adherent and suspension culture.. Orthopaedic Research Society 56th Annual Meeting 2010, Seattle, WA.
            12. Goodrich LR, Choi VW, Carbone BA, McIlwraith CW, Samulski RJ. Ex vivo serotype-specific transduction of equine joint tissue by self-complementary adeno-associated viral vectors.. Hum Gene Ther 2009 Dec;20(12):1697-702.
              pmc: PMC2861962pubmed: 19642864doi: 10.1089/hum.2009.030google scholar: lookup
            13. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.. J Infect Dis 2009 Feb 1;199(3):381-90.
              pubmed: 19133809doi: 10.1086/595830google scholar: lookup
            14. Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, Masurier C. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.. Hum Gene Ther 2010 Jun;21(6):704-12.
              pubmed: 20095819doi: 10.1089/hum.2009.182google scholar: lookup
            15. Erles K, Sebökovà P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV).. J Med Virol 1999 Nov;59(3):406-11.
              pubmed: 10502275doi: 10.1002/(sici)1096-9071(199911)59:3<406::aid-jmv22>3.0.co;2-ngoogle scholar: lookup
            16. Petry H, Brooks A, Orme A, Wang P, Liu P, Xie J, Kretschmer P, Qian HS, Hermiston TW, Harkins RN. Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice.. Gene Ther 2008 Jan;15(1):54-60.
              pubmed: 17960164doi: 10.1038/sj.gt.3303037google scholar: lookup
            17. Scallan CD, Jiang H, Liu T, Patarroyo-White S, Sommer JM, Zhou S, Couto LB, Pierce GF. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice.. Blood 2006 Mar 1;107(5):1810-7.
              pubmed: 16249376doi: 10.1182/blood-2005-08-3229google scholar: lookup
            18. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle B, Dake M, Kaye R, Razavi M, Zajko A, Zehnder J, Rustagi PK, Nakai H, Chew A, Leonard D, Wright JF, Lessard RR, Sommer JM, Tigges M, Sabatino D, Luk A, Jiang H, Mingozzi F, Couto L, Ertl HC, High KA, Kay MA. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.. Nat Med 2006 Mar;12(3):342-7.
              pubmed: 16474400doi: 10.1038/nm1358google scholar: lookup
            19. Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, Rasko JE, Ragni MV, Manno CS, Sommer J, Jiang H, Pierce GF, Ertl HC, High KA. CD8(+) T-cell responses to adeno-associated virus capsid in humans.. Nat Med 2007 Apr;13(4):419-22.
              pubmed: 17369837doi: 10.1038/nm1549google scholar: lookup
            20. Mingozzi F, Meulenberg JJ, Hui DJ, Basner-Tschakarjan E, Hasbrouck NC, Edmonson SA, Hutnick NA, Betts MR, Kastelein JJ, Stroes ES, High KA. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells.. Blood 2009 Sep 3;114(10):2077-86.
              pmc: PMC2744569pubmed: 19506302doi: 10.1182/blood-2008-07-167510google scholar: lookup
            21. Veron P, Leborgne C, Monteilhet V, Boutin S, Martin S, Moullier P, Masurier C. Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors.. J Immunol 2012 Jun 15;188(12):6418-24.
              pubmed: 22593612doi: 10.4049/jimmunol.1200620google scholar: lookup
            22. Li H, Lasaro MO, Jia B, Lin SW, Haut LH, High KA, Ertl HC. Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primates.. Mol Ther 2011 Nov;19(11):2021-30.
              pmc: PMC3222540pubmed: 21587208doi: 10.1038/mt.2011.81google scholar: lookup
            23. Matsushita T, Elliger S, Elliger C, Podsakoff G, Villarreal L, Kurtzman GJ, Iwaki Y, Colosi P. Adeno-associated virus vectors can be efficiently produced without helper virus.. Gene Ther 1998 Jul;5(7):938-45.
              pubmed: 9813665doi: 10.1038/sj.gt.3300680google scholar: lookup
            24. American Association of Equine Practitioners. Guide for Veterinary Service and Judging of Equestrian Events. AAEP Monograph 1991; pp. 19–27.
            25. Wagner B, Freer H. Development of a bead-based multiplex assay for simultaneous quantification of cytokines in horses.. Vet Immunol Immunopathol 2009 Feb 15;127(3-4):242-8.
              pubmed: 19027964doi: 10.1016/j.vetimm.2008.10.313google scholar: lookup
            26. Wagner B, Ainsworth DM, Freer H. Analysis of soluble CD14 and its use as a biomarker in neonatal foals with septicemia and horses with recurrent airway obstruction.. Vet Immunol Immunopathol 2013 Sep 1;155(1-2):124-8.
              pubmed: 23810420doi: 10.1016/j.vetimm.2013.05.018google scholar: lookup
            27. Gao G, Qu G, Burnham MS, Huang J, Chirmule N, Joshi B, Yu QC, Marsh JA, Conceicao CM, Wilson JM. Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo.. Hum Gene Ther 2000 Oct 10;11(15):2079-91.
              pubmed: 11044910doi: 10.1089/104303400750001390google scholar: lookup
            28. Goodman LB, Wagner B, Flaminio MJ, Sussman KH, Metzger SM, Holland R, Osterrieder N. Comparison of the efficacy of inactivated combination and modified-live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1).. Vaccine 2006 Apr 24;24(17):3636-45.
              pubmed: 16513225doi: 10.1016/j.vaccine.2006.01.062google scholar: lookup
            29. Wagner B, Radbruch A, Rohwer J, Leibold W. Monoclonal anti-equine IgE antibodies with specificity for different epitopes on the immunoglobulin heavy chain of native IgE.. Vet Immunol Immunopathol 2003 Mar 20;92(1-2):45-60.
              pubmed: 12628763doi: 10.1016/s0165-2427(03)00007-2google scholar: lookup
            30. Wagner B, Burton A, Ainsworth D. Interferon-gamma, interleukin-4 and interleukin-10 production by T helper cells reveals intact Th1 and regulatory TR1 cell activation and a delay of the Th2 cell response in equine neonates and foals.. Vet Res 2010 Jul-Aug;41(4):47.
              pmc: PMC2865874pubmed: 20374696doi: 10.1051/vetres/2010019google scholar: lookup
            31. Burton AB, Wagner B, Erb HN, Ainsworth DM. Serum interleukin-6 (IL-6) and IL-10 concentrations in normal and septic neonatal foals.. Vet Immunol Immunopathol 2009 Dec 15;132(2-4):122-8.
              pubmed: 19501415doi: 10.1016/j.vetimm.2009.05.006google scholar: lookup
            32. Goater J, Müller R, Kollias G, Firestein GS, Sanz I, O'Keefe RJ, Schwarz EM. Empirical advantages of adeno associated viral vectors in vivo gene therapy for arthritis.. J Rheumatol 2000 Apr;27(4):983-9.
              pubmed: 10782827
            33. Gouze E, Gouze JN, Palmer GD, Pilapil C, Evans CH, Ghivizzani SC. Transgene persistence and cell turnover in the diarthrodial joint: implications for gene therapy of chronic joint diseases.. Mol Ther 2007 Jun;15(6):1114-20.
              pubmed: 17440444doi: 10.1038/sj.mt.6300151google scholar: lookup
            34. Jiang H, Couto LB, Patarroyo-White S, Liu T, Nagy D, Vargas JA, Zhou S, Scallan CD, Sommer J, Vijay S, Mingozzi F, High KA, Pierce GF. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy.. Blood 2006 Nov 15;108(10):3321-8.
              pmc: PMC1895424pubmed: 16868252doi: 10.1182/blood-2006-04-017913google scholar: lookup
            35. Pien GC, Basner-Tschakarjan E, Hui DJ, Mentlik AN, Finn JD, Hasbrouck NC, Zhou S, Murphy SL, Maus MV, Mingozzi F, Orange JS, High KA. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors.. J Clin Invest 2009 Jun;119(6):1688-95.
              pmc: PMC2689109pubmed: 19436115doi: 10.1172/jci36891google scholar: lookup
            36. Mueller C, Chulay JD, Trapnell BC, Humphries M, Carey B, Sandhaus RA, McElvaney NG, Messina L, Tang Q, Rouhani FN, Campbell-Thompson M, Fu AD, Yachnis A, Knop DR, Ye GJ, Brantly M, Calcedo R, Somanathan S, Richman LP, Vonderheide RH, Hulme MA, Brusko TM, Wilson JM, Flotte TR. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression.. J Clin Invest 2013 Dec;123(12):5310-8.
              pmc: PMC3859421pubmed: 24231351doi: 10.1172/jci70314google scholar: lookup
            37. Martino AT, Suzuki M, Markusic DM, Zolotukhin I, Ryals RC, Moghimi B, Ertl HC, Muruve DA, Lee B, Herzog RW. The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver.. Blood 2011 Jun 16;117(24):6459-68.
              pmc: PMC3123017pubmed: 21474674doi: 10.1182/blood-2010-10-314518google scholar: lookup
            38. Cottard V, Valvason C, Falgarone G, Lutomski D, Boissier MC, Bessis N. Immune response against gene therapy vectors: influence of synovial fluid on adeno-associated virus mediated gene transfer to chondrocytes.. J Clin Immunol 2004 Mar;24(2):162-9.
              pubmed: 15024183doi: 10.1023/b:joci.0000019781.64421.5cgoogle scholar: lookup
            39. Mingozzi F, Chen Y, Edmonson SC, Zhou S, Thurlings RM, Tak PP, High KA, Vervoordeldonk MJ. Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue.. Gene Ther 2013 Apr;20(4):417-24.
              pmc: PMC3473155pubmed: 22786533doi: 10.1038/gt.2012.55google scholar: lookup
            40. Boissier MC, Lemeiter D, Clavel C, Valvason C, Laroche L, Begue T, Bessis N. Synoviocyte infection with adeno-associated virus (AAV) is neutralized by human synovial fluid from arthritis patients and depends on AAV serotype.. Hum Gene Ther 2007 Jun;18(6):525-35.
              pubmed: 17532727doi: 10.1089/hum.2006.174google scholar: lookup

            Citations

            This article has been cited 5 times.
            1. Toyoda E, Maehara M, Watanabe M, Sato M. Candidates for Intra-Articular Administration Therapeutics and Therapies of Osteoarthritis.. Int J Mol Sci 2021 Mar 30;22(7).
              doi: 10.3390/ijms22073594pubmed: 33808364google scholar: lookup
            2. Chen Q, Luo H, Zhou C, Yu H, Yao S, Fu F, Seeley R, Ji X, Yang Y, Chen P, Jin H, Tong P, Chen D, Wu C, Du W, Ruan H. Comparative intra-articular gene transfer of seven adeno-associated virus serotypes reveals that AAV2 mediates the most efficient transduction to mouse arthritic chondrocytes.. PLoS One 2020;15(12):e0243359.
              doi: 10.1371/journal.pone.0243359pubmed: 33320893google scholar: lookup
            3. Moss KL, Jiang Z, Dodson ME, Linardi RL, Haughan J, Gale AL, Grzybowski C, Engiles JE, Stefanovski D, Robinson MA, Ortved KF. Sustained Interleukin-10 Transgene Expression Following Intra-Articular AAV5-IL-10 Administration to Horses.. Hum Gene Ther 2020 Jan;31(1-2):110-118.
              doi: 10.1089/hum.2019.195pubmed: 31773987google scholar: lookup
            4. Watson Levings RS, Smith AD, Broome TA, Rice BL, Gibbs EP, Myara DA, Hyddmark EV, Nasri E, Zarezadeh A, Levings PP, Lu Y, White ME, Dacanay EA, Foremny GB, Evans CH, Morton AJ, Winter M, Dark MJ, Nickerson DM, Colahan PT, Ghivizzani SC. Self-Complementary Adeno-Associated Virus-Mediated Interleukin-1 Receptor Antagonist Gene Delivery for the Treatment of Osteoarthritis: Test of Efficacy in an Equine Model.. Hum Gene Ther Clin Dev 2018 Jun;29(2):101-112.
              doi: 10.1089/humc.2017.143pubmed: 29869535google scholar: lookup
            5. Zhao S, Sun Y, Li X, Wang J, Yan L, Chen H, Wang D, Dai J, He J. Reduction of intraarticular adhesion of knee by local application of rapamycin in rabbits via inhibition of fibroblast proliferation and collagen synthesis.. J Orthop Surg Res 2016 Apr 19;11:45.
              doi: 10.1186/s13018-016-0375-0pubmed: 27094512google scholar: lookup
            Subscribe to our newsletter
            Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.